EWTX Edgewise Therapeutics, Inc.

Nasdaq edgewisetx.com


$ 16.09 $ 0.86 (5.65 %)    

Monday, 27-Oct-2025 15:40:23 EDT
QQQ $ 627.50 $ 0.00 (0 %)
DIA $ 475.09 $ 0.29 (0.06 %)
SPY $ 684.57 $ 1.79 (0.26 %)
TLT $ 91.75 $ 0.44 (0.48 %)
GLD $ 367.12 $ -3.89 (-1.05 %)
$ 15.18
$ 15.23
$ 15.98 x 700
$ 16.10 x 100
$ 15.40 - $ 16.37
$ 10.60 - $ 38.12
433,601
na
1.6B
$ 1.60
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 03-03-2025 12-31-2024 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 02-22-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 02-23-2023 12-31-2022 10-K
12 11-03-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 05-11-2022 03-31-2022 10-Q
15 02-24-2022 12-31-2021 10-K
16 11-10-2021 09-30-2021 10-Q
17 08-09-2021 06-30-2021 10-Q
18 05-13-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 jp-morgan-maintains-overweight-on-edgewise-therapeutics-lowers-price-target-to-30

JP Morgan analyst Tessa Romero maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Overweight and lowers the price target f...

 rbc-capital-maintains-outperform-on-edgewise-therapeutics-raises-price-target-to-49

RBC Capital analyst Leonid Timashev maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and raises the price tar...

 edgewise-therapeutics-q2-eps-034-beats-043-estimate

Edgewise Therapeutics (NASDAQ:EWTX) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of...

 hc-wainwright--co-initiates-coverage-on-edgewise-therapeutics-with-buy-rating-announces-price-target-of-42

HC Wainwright & Co. analyst Joseph Pantginis initiates coverage on Edgewise Therapeutics (NASDAQ:EWTX) with a Buy rating...

 no-accelerated-fda-approval-for-edgewises-rare-muscular-disease-drug-shares-fall

Edgewise reports sustained functional stability in Becker patients and selects Phase 3 dose for Duchenne after positive Phase 2...

 edgewise-therapeutics-reports-results-in-sevasemten-program-for-becker-and-duchenne-muscular-dystrophies

Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today unveiled positive results...

 rbc-capital-reiterates-outperform-on-edgewise-therapeutics-maintains-48-price-target

RBC Capital analyst Leonid Timashev reiterates Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and maintains $48 price...

 edgewise-therapeutics-q1-eps-043-inline

Edgewise Therapeutics (NASDAQ:EWTX) reported quarterly losses of $(0.43) per share which met the analyst consensus estimate. Th...

 wedbush-maintains-outperform-on-edgewise-therapeutics-maintains-43-price-target

Wedbush analyst Laura Chico maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and maintains $43 price target.

 rbc-capital-maintains-outperform-on-edgewise-therapeutics-lowers-price-target-to-52

RBC Capital analyst Leonid Timashev maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and lowers the price tar...

 scotiabank-downgrades-edgewise-therapeutics-to-sector-perform-lowers-price-target-to-14

Scotiabank analyst Louise Chen downgrades Edgewise Therapeutics (NASDAQ:EWTX) from Sector Outperform to Sector Perform and l...

 piper-sandler-maintains-overweight-on-edgewise-therapeutics-maintains-51-price-target

Piper Sandler analyst Yasmeen Rahimi maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Overweight and maintains $51 price...

 edgewise-therapeutics-sees-meaningful-hcm-treatment-gains-with-edg-7500-in-phase-2-study

Edgewise's EDG-7500 lowered LVOT gradient and NT-proBNP levels in HCM patients, improving symptoms. Initial Part D data is ...

 why-edgewise-therapeutics-ewtx-stock-is-falling

Edgewise Therapeutics shares are trading lower by 25.7% during Wednesday's session. The company announced an approximate $2...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION